In the fight against cancer, one aspect receives relatively less attention from investors in the healthcare sector—the ability to detect the disease early, providing doctors with a genuine opportunity for treatment. Cancer diagnostics is one of the fastest-growing fields in medicine. A study by Precedence Research predicts that its global market size will grow at a compound annual growth rate of 8.33% between 2026 and 2035, reaching $378.4 billion. Progress is being made in numerous areas. For example, the combination of artificial intelligence and cancer imaging is becoming a powerful force, enabling more accurate detection.
Telix Pharmaceuticals (TLX) is an Australian nuclear medicine company dedicated to developing targeted cancer molecules that can attach to radioisotopes. When these molecules bind to cancer cells in the body, the attached isotopes can be used to detect cancer—or, if attached to more potent radioisotopes, can kill the diseased cells.
This biotechnology company, founded only 10 years ago, is still relatively unknown, but there are three reasons suggesting that investing in its stock could generate generational wealth for shareholders.
Telix announced its 2025 results on February 20. Full-year revenue was $804 million, a 56% increase year-over-year. Management expects 2026 revenue to be between $950 million and $970 million, representing 19% growth at the midpoint. This optimistic outlook stems from the sales progress of its leading products, Illuccix and Gozellix.
These two drugs can be injected by healthcare providers to help identify prostate-specific membrane antigen positive cells via PET scans. The company is seeing increasing regulatory approvals for Illuccix and recently launched Gozellix in the United States. As these therapies gain approval in more countries, their growing adoption will help Telix fund its research and development pipeline.
Telix has two key drugs in Phase 3 clinical trials: TLX591 and TLX250. TLX591 is a molecule that helps target and treat prostate cancer. TLX250 is used for kidney cancer. Both therapies can be attached to low-energy isotopes for detection, or to high-energy isotopes to release enough radiation to kill the cancer cells they bind to, ideally while protecting nearby healthy tissue. The company is also working to broaden its product portfolio, currently seeking approvals for Zircaix (for kidney cancer) and Pixclara (for brain cancer).
Last year, Telix completed the acquisition of RLS Pharmacies, a network of 31 radiopharmacies across the United States, for $250 million. This has allowed it to build an integrated ecosystem that most of its peers lack.
Analysts covering Telix appear optimistic about the stock. Their average price target for the next 12 months is $21.30, more than three times its current share price (below $7). Therefore, it presents a good medium-term opportunity for investors, and potentially an even better long-term opportunity if its pipeline candidates succeed.
